New drug targets brain tumors before surgery in early trial
NCT ID NCT06636162
First seen Mar 01, 2026 · Last updated Jun 13, 2026 · Updated 15 times
Summary
This early study tests an oral drug called DSP-0390 in 20 people with IDH-mutant gliomas (a type of brain tumor) who are scheduled for surgery. Participants take the drug for about 2 weeks before their tumor is removed. Researchers measure how much drug reaches the tumor and blood, and look for changes in cholesterol-related markers. The goal is to learn if the drug can build up in the tumor and kill cancer cells, not to provide a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.